Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07735533 | A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies | not yet recruiting | Phase 1 / Phase 2 | 274 | Umoja BiopharmaINDUSTRY | 0 | Aug 17, 2026 | clinicaltrials |
| NCT07735546 | A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 100 | Umoja BiopharmaINDUSTRY | 0 | Aug 17, 2026 | clinicaltrials |
| NCT03843294 |
| Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma |
| active not recruiting |
| Phase 1 |
| 18 |
| Catherine BollardOTHER |
| 1 |
| Aug 14, 2026 |
| clinicaltrials |
| NCT04447027 | Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05675449 | A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma(MagnetisMM-20) | active not recruiting | Phase 1 | 59 | PfizerINDUSTRY | 2 | Aug 13, 2026 | clinicaltrials |
| NCT06622005 | SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06762431 | Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.(VTB-CLL002) | recruiting | Phase 1 / Phase 2 | 24 | Vitebsk Regional Clinical Cancer CentreOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06980116 | Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies | recruiting | Phase 1 | 85 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
| NCT07463807 | Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment | recruiting | Phase 1 / Phase 2 | 162 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07649304 | AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") | not yet recruiting | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 0 | Aug 13, 2026 | clinicaltrials |
| NCT03440567 | Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma | completed | Phase 1 | 16 | City of Hope Medical CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04354246 | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies | completed | Phase 1 | 94 | Compugen LtdINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04468841 | Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma | active not recruiting | Phase 1 | 77 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06340737 | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | recruiting | Phase 1 | 148 | Stanford UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07280013 | A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects | recruiting | Phase 1 | 60 | C4 Therapeutics, Inc.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07311746 | Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia | recruiting | Phase 1 / Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07754890 | Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 65 | Peking Union Medical College HospitalOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07759102 | Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma | not yet recruiting | Phase 1 | 20 | University of California, DavisOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT02889523 | Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy(Epi-RCHOP) | active not recruiting | Phase 1 / Phase 2 | 214 | The Lymphoma Academic Research OrganisationOTHER | 2 | Aug 11, 2026 | clinicaltrials |
| NCT04443829 | Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma(CAROUSEL) | active not recruiting | Phase 1 | 12 | University College, LondonOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05646836 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma | active not recruiting | Phase 1 | 90 | Genentech, Inc.INDUSTRY | 7 | Aug 11, 2026 | clinicaltrials |
| NCT07603479 | JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 14 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07758673 | Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma | not yet recruiting | Phase 1 | 16 | City of Hope Medical CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05075603 | Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy | completed | Phase 1 | 17 | NeoImmuneTechINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05887167 | Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies | recruiting | Phase 1 | 20 | Joshua Sasine, MD, PhDOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05976555 | Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma | recruiting | Phase 1 | 30 | Medical College of WisconsinOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06105554 | Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07221032 | FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 12 | Medical College of WisconsinOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07451054 | CD45BE-HSPC + CART-45 Cells | recruiting | Phase 1 | 42 | University of PennsylvaniaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03504644 | Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 7, 2026 | clinicaltrials |
| NCT05020444 | TriPRIL CAR T Cells in Multiple Myeloma | active not recruiting | Phase 1 | 16 | Marcela V. Maus, M.D.,Ph.D.OTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05092451 | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances | recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05632380 | ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07661537 | A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 90 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05535244 | A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma(CAMMA 2) | active not recruiting | Phase 1 / Phase 2 | 90 | Hoffmann-La RocheINDUSTRY | 8 | Aug 6, 2026 | clinicaltrials |
| NCT05990465 | LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | recruiting | Phase 1 | 12 | Medical College of WisconsinOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06533579 | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | recruiting | Phase 1 / Phase 2 | 32 | Vironexis Biotherapeutics Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07518329 | Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.(SAPPHIRE) | not yet recruiting | Phase 1 | 46 | Arovella Therapeutics LtdINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749976 | GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 108 | VitruviaeINDUSTRY | 0 | Aug 6, 2026 | clinicaltrials |
| NCT02291848 | Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma(TACTAM) | active not recruiting | Phase 1 | 36 | Baylor College of MedicineOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06669247 | A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma(COSTIMM) | recruiting | Phase 1 / Phase 2 | 186 | Regeneron PharmaceuticalsINDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT06675123 | Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07742527 | A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care(DynaMMic-2) | not yet recruiting | Phase 1 | 22 | GlaxoSmithKlineINDUSTRY | 0 | Aug 3, 2026 | clinicaltrials |
| NCT03011814 | Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 78 | City of Hope Medical CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03091257 | A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 30 | Massachusetts General HospitalOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04652960 | Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome | active not recruiting | Phase 1 | 38 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04847453 | Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis | active not recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06708897 | A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies | recruiting | Phase 1 | 84 | Lomond Therapeutics Holdings, Inc.INDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06965114 | Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia | recruiting | Phase 1 / Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 17, 2026source: clinicaltrials